This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
Heico Corporation (HEI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Heico (HEI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HEIPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Earnings Preview: PDD Holdings Inc. Sponsored ADR (PDD) Q2 Earnings Expected to Decline
by Zacks Equity Research
PDD Holdings Inc. Sponsored ADR (PDD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PDDNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 101% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
RAPTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 106.2% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
XOMAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 149.7% in Mineralys Therapeutics, Inc. (MLYS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MLYSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Kiniksa Pharmaceuticals International, plc (KNSA) Could Rally 26.69%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 26.7% upside potential for Kiniksa Pharmaceuticals International, plc (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
KNSAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Brainsway (BWAY) Could Surge 25.58%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Brainsway (BWAY) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BWAYPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Enovis (ENOV) Have the Potential to Rally 77.33% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ENOVNo Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CRMDPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
BJ's Wholesale Club (BJ) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BJ's (BJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BJPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TRMLNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Harrow (HROW) points to a 53.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
HROWNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PASGPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Ardmore Shipping (ASC)? Wall Street Analysts Think 25.55%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in Ardmore Shipping (ASC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ASCPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Astria Therapeutics (ATXS) points to a 333.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ATXSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in The Pennant Group (PNTG)? Wall Street Analysts Think 31.17%
by Zacks Equity Research
The mean of analysts' price targets for The Pennant Group (PNTG) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PNTGNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 28.68% Upside in West Pharmaceutical (WST): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for West Pharmaceutical (WST) points to a 28.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
WSTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
SelectQuote (SLQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
SelectQuote (SLQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SLQTPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate VNET Group (VNET) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
VNET Group (VNET) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VNETNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Walmart (WMT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Walmart (WMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WMTPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Bilibili (BILI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Bilibili (BILI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BILIPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Ross Stores (ROST) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ross Stores (ROST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ROSTNegative Net Change TJXPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AMRXNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ARQTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 187.7% upside potential for Bicara Therapeutics Inc. (BCAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BCAXNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate